http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2013334610-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_742c986fcadce9cf6b12acd18c590ee1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_61f88efcda59d7062a4252ecf6886f58 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1793 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2086 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 |
| filingDate | 2013-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f19d0b296efcda79464199c4963cb723 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b71ee4360c67ad8981d0615ce2e7d566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb1c274d6291fba696344d000b4c2b6b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4feebc8325f2d10d02e22644458fce58 |
| publicationDate | 2015-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2013334610-A1 |
| titleOfInvention | IL-15R alpha forms, cells expressing IL-15R alpha forms, and therapeutic uses of IL-15R alpha and IL-15/IL-15R alpha complexes |
| abstract | In one aspect, described herein are cyclical administration regimens for the administration of complexes comprising interleukin-15 ("IL-15") covalently or noncovalently bound to IL-15 receptor alpha ("IL-15Ra") to patients in order to enhance IL-15-mediated immune function. In a specific aspect, the cyclical administration regimens are useful in the prevention, treatment, and/or management of disorders in which enhancing IL-15-mediated function is beneficial, such as cancer, infectious diseases, immune deficiencies and lymphopenia. Also described herein are purified soluble forms of IL-15Ra, cells that recombinantly express soluble forms ofiL-15Ra, and compositions comprising complexes of IL-15 covalently or non-covalently bound to soluble forms ofiL-15Ra. Further described herein are host cells that recombinantly express IL15-Ra derivatives comprising a mutation or deletion in the extracellular domain cleavage site, including IL-15Ra derivatives comprising the extracellular domain of IL-15Ra and a transmembrane domain of a heterologous molecule. |
| priorityDate | 2012-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 3603.